

## PI Industries

Estimate change	↔
TP change	↔
Rating change	↔

Bloomberg	PI IN
Equity Shares (m)	152
M.Cap.(INRb)/(USDb)	440.2 / 4.5
52-Week Range (INR)	4330 / 2700
1, 6, 12 Rel. Per (%)	-2/-6/-18
12M Avg Val (INR M)	864

### Financials & Valuations (INR b)

Y/E Mar	2026	2027E	2028E
Sales	67.1	74.8	85.9
EBITDA	17.0	19.1	22.8
PAT	12.4	13.7	16.3
EBITDA (%)	25.3	25.6	26.5
EPS (INR)	81.8	89.9	107.1
EPS Gr. (%)	(25.1)	9.9	19.2
BV/Sh. (INR)	739	813	904

### Ratios

Net D/E	(0.3)	(0.3)	(0.4)
RoE (%)	11.6	11.6	12.5
RoCE (%)	11.5	11.4	12.3
Payout (%)	18.4	17.8	14.9

### Valuations

P/E (x)	35.5	32.3	27.1
EV/EBITDA (x)	24.8	21.6	17.8
Div Yield (%)	0.6	0.6	0.6
FCF Yield (%)	(1.1)	2.7	2.8

### Shareholding Pattern (%)

As on	Mar-26	Dec-25	Mar-25
Promoter	46.1	46.1	46.1
DII	31.3	31.1	27.6
FII	15.9	16.0	18.1
Others	6.7	6.9	8.3

Note: FII includes depository receipts

**CMP: INR2,901**      **TP: INR3,500 (+21%)**      **Buy**

## Weak CSM volume offtake weighs on performance

### Operating performance misses our estimate

- PI Industries (PI) reported a weak quarter as revenue declined 12% YoY, primarily due to a 15% YoY dip in the CSM business, attributed to the global slowdown and cautious customer scheduling (volume declined 14% YoY). Domestic Agri also reported a revenue decline of 9% YoY, while the Pharma business grew 23% YoY. Gross margins expanded 280bp YoY due to a better product mix and operational efficiency, while lower volumes led to adverse operating leverage, thereby resulting in an overall EBITDA margin contraction of 400bp YoY.
- Going forward, we remain cautiously optimistic on FY27, supported by a strong order book, committed customer offtake plans, and the planned launch of over 5+ new molecules in the CSM business, which should accelerate growth in 2HFY27. In addition, the Biologicals pipeline and potential inorganic opportunities continue to strengthen the growth outlook.
- We largely maintain our FY27/FY28 earnings estimates and **reiterate our BUY rating with a TP of INR3,500 (based on 33x FY28E EPS, i.e. a discount of ~10% to the company's six-year historical P/E at 37x).**

### Adverse operating leverage contracts margins

- Revenue stood at INR15.7b (est. in line), declining 12% YoY. Agrochemicals business revenue declined 14% YoY to INR14.6b, and the Pharma business revenue rose 23% YoY to INR1b.
- EBITDA stood at INR3.4b (est. INR3.8b), declining 26% YoY. EBITDA margins contracted 400bp YoY to 21.5% (est. 24.1%); gross margins stood at 58% (up 280bp YoY); employee expenses rose 350bp YoY to 14.5%; other expenses rose 330bp YoY to 21.8% of sales.
- For FY26, Agrochemicals business revenue declined 17% to INR64b, while Pharma business revenue grew 40% to INR3b.
- EBIT margins for the Agrochemical business stood at 22.8% (down 660bp), and the Pharma business reported an operating loss of INR486m vs an operating loss of INR821m in 4QFY25. Adj. PAT declined 39% YoY to INR2.0b (est. INR2.7b).
- For FY26, EBIT margins for the agrochemical business stood at 28.0% (down 280bp), and the pharma business reported an operating loss of INR2.7b vs an operating loss of INR3b in FY25.
- For FY26, Revenue/EBITDA/Adj PAT declined 16%/22%/25% to INR67b/INR17b/INR12b.
- Gross debt stood at INR2.4b vs INR1.1b as of Mar'25. CFO stood at INR4.7b vs INR14.1b as of Mar'25.
- PAT was adjusted for a one-time labor code adjustment of INR20m.

**Sumant Kumar - Research Analyst** (Sumant.Kumar@MotilalOswal.com)/ **Meet Jain** (Meet.Jain@MotilalOswal.com)

**Research Analyst: Nirvik Saini** (Nirvik.Saini@MotilalOswal.com)/ **Yash Darak** (Yash.Darak@MotilalOswal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**

Motilal Oswal research is available on [www.motilaloswal.com/Institutional-Equities](http://www.motilaloswal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

### Highlights from the management commentary

- **Electronic Chemicals:** The business is currently in the ramp-up phase, focusing on niche and differentiated applications, with strong investments being made to scale the segment. With several products under development, management expects better visibility on the revenue potential over the next 4–5 years, with the segment expected to contribute INR100m in revenue.
- **Pharma:** Revenue growth was driven by the addition of new customers, including strategic accounts and large pharma clients, providing strong medium- to long-term growth visibility. Margins remained under pressure due to one-off processing costs, unfavorable product mix, and higher overheads related to capability building, talent addition, and process enhancement initiatives. Although the business may take a couple of years to achieve positive EBITDA, management is targeting CDMO revenue of INR5-6b over the next 2-3 years.
- **Biologics:** The company has introduced a first-of-its-kind foliar application-based biological nematode product, differentiated from the predominantly soil-applied alternatives in the market. The product has been launched in Brazil and Mexico, with the US emerging as another key market, and management expects sales to more than triple this year, driven by strong farmer feedback and competitive performance versus synthetic chemistry products.

### Valuation and view


- The company's CSM business witnessed a sharp slowdown in FY26 due to weak industry demand, elevated channel inventories globally, and customers adopting a cautious just-in-time procurement strategy, resulting in a volume decline.
- Going forward, we believe growth recovery will be led by: 1) improving growth prospects in the CSM business due to faster growth in new molecules (commercialization of 20+ molecules over the last few years), ramp up of new molecules (18-20% share), strong pipeline of 90+ molecules (>60% in advanced stages of development); 2) robust pipeline of biological products across various development stages; and 3) the ramp-up of its pharma business with profitable growth.
- We expect a CAGR of 13%/16%/14% in revenue/EBITDA/adj. PAT over FY26-28. **We reiterate our BUY rating with a TP of INR3,500 (based on 33x FY28E EPS, i.e. a discount of ~10% to the company's six-year historical P/E at 37x).**

**Quarterly Earning Model**


Y/E March	(INRm)											
	FY25				FY26				FY25	FY26	FY26E	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4Q	(%)
<b>Net Sales</b>	<b>20,689</b>	<b>22,210</b>	<b>19,008</b>	<b>17,871</b>	<b>19,005</b>	<b>18,723</b>	<b>13,757</b>	<b>15,652</b>	<b>79,778</b>	<b>67,137</b>	<b>15,574</b>	<b>0</b>
YoY Change (%)	8.3	4.9	0.2	2.6	-8.1	-15.7	-27.6	-12.4	4.1	-15.8	-12.9	
Total Expenditure	14,857	15,928	13,888	13,315	13,814	13,310	10,734	12,283	57,988	50,141	11,818	
<b>EBITDA</b>	<b>5,832</b>	<b>6,282</b>	<b>5,120</b>	<b>4,556</b>	<b>5,191</b>	<b>5,413</b>	<b>3,023</b>	<b>3,369</b>	<b>21,790</b>	<b>16,996</b>	<b>3,756</b>	<b>-10</b>
Margins (%)	28.2	28.3	26.9	25.5	27.3	28.9	22.0	21.5	27.3	25.3	24.1	
Depreciation	834	798	991	902	965	980	1,054	1,067	3,525	4,066	1,090	
Interest	83	85	83	79	39	26	62	37	330	164	50	
Other Income	727	1,222	759	734	859	825	667	756	3,442	3,107	850	
<b>PBT before EO expense</b>	<b>5,642</b>	<b>6,621</b>	<b>4,805</b>	<b>4,309</b>	<b>5,046</b>	<b>5,232</b>	<b>2,574</b>	<b>3,021</b>	<b>21,377</b>	<b>15,873</b>	<b>3,466</b>	
Extra-Ord expense	0	0	0	0	0	0	-1,051	20	0	-1,031	0	
<b>PBT</b>	<b>5,642</b>	<b>6,621</b>	<b>4,805</b>	<b>4,309</b>	<b>5,046</b>	<b>5,232</b>	<b>3,625</b>	<b>3,001</b>	<b>21,377</b>	<b>16,904</b>	<b>3,466</b>	
Tax	1,175	1,546	1,080	1,017	1,074	1,160	516	1,003	4,818	3,753	797	
Rate (%)	20.8	23.3	22.5	23.6	21.3	22.2	14.2	33.4	22.5	22.2	23.0	
MI & Profit/Loss of Asso. Cos.	-21	-7	-2	-13	-28	-21	-4	-4	-43	-57	-15	
<b>Reported PAT</b>	<b>4,488</b>	<b>5,082</b>	<b>3,727</b>	<b>3,305</b>	<b>4,000</b>	<b>4,093</b>	<b>3,113</b>	<b>2,002</b>	<b>16,602</b>	<b>13,208</b>	<b>2,684</b>	
<b>Adj PAT</b>	<b>4,488</b>	<b>5,082</b>	<b>3,727</b>	<b>3,305</b>	<b>4,000</b>	<b>4,093</b>	<b>2,325</b>	<b>2,017</b>	<b>16,602</b>	<b>12,435</b>	<b>2,684</b>	<b>-25</b>
YoY Change (%)	17.2	5.8	-16.9	-10.6	-10.9	-19.5	-37.6	-39.0	-1.3	-25.1	-19	
Margins (%)	21.7	22.9	19.6	18.5	21.0	21.9	16.9	12.9	20.8	18.5	17.2	

**Key Performance Indicators**

Y/E March	FY25				FY26				FY25	FY26E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
<b>CSM Revenue (INRm)</b>	<b>17,241</b>	<b>17,199</b>	<b>15,565</b>	<b>13,638</b>	<b>14,897</b>	<b>14,105</b>	<b>10,574</b>	<b>11,537</b>	<b>63,643</b>	<b>51,113</b>
% Change	13.5	10.2	3.5	-2.5	-13.6	-18.0	-32.1	-15.4	6.4	-19.7
<b>Domestic Formulation (INRm)</b>	<b>3,195</b>	<b>4,600</b>	<b>2,806</b>	<b>3,383</b>	<b>3,385</b>	<b>3,984</b>	<b>2,584</b>	<b>3,067</b>	<b>13,984</b>	<b>13,020</b>
% Change	-8.0	-5.0	5.3	24.9	5.9	-13.4	-7.9	-9.3	2.2	-6.9
<b>Pharma</b>	<b>253</b>	<b>411</b>	<b>637</b>	<b>850</b>	<b>723</b>	<b>634</b>	<b>599</b>	<b>1,048</b>	<b>2,151</b>	<b>3,004</b>
% Change	-42.9	-42.8	-50.0	18.9	185.8	54.3	-6.0	23.3	-31.7	39.7
<b>Cost Break-up</b>										
RM Cost (% of sales)	48.2	48.2	47.3	44.9	42.6	42.7	41.0	42.2	47.3	42.2
Staff Cost (% of sales)	9.7	8.8	10.0	11.0	12.2	11.8	16.6	14.5	9.8	13.5
Other Cost (% of sales)	13.9	14.7	15.7	18.5	17.9	16.6	20.5	21.8	15.6	19.0
Gross Margins (%)	51.8	51.8	52.7	55.1	57.4	57.3	59.0	57.8	52.7	57.8
EBITDA Margins (%)	28.2	28.3	26.9	25.5	27.3	28.9	22.0	21.5	27.3	25.3
EBIT Margins (%)	24.2	24.7	21.7	20.4	22.2	23.7	14.3	14.7	22.9	19.3

**Exhibit 1: One year forward P/E**



Source: Company, MOFSL

**Exhibit 2: One year forward P/B**


Source: Company, MOFSL


## Key exhibits

**Exhibit 3: Revenue growth trend**




Source: Company, MOFSL

**Exhibit 4: EBITDA trend**




Source: Company, MOFSL

**Exhibit 5: PAT trend**




Source: Company, MOFSL

**Exhibit 6: CSM revenue trend**







Source: Company, MOFSL

**Exhibit 7: Revenue trend in agri inputs**



Source: Company, MOFSL

**Exhibit 8: Momentum of new product launches to continue**

 <p><b>Alcor®</b> Systemicherbicide for management of ALS resistance weeds</p>		 <p><b>Comet®</b> Post emergent herbicide for control of grasses</p>		 <p><b>Uranus®</b> For Mites control</p>		 <p><b>Fixit®</b> Herbicide for Rice weeds control</p>	
 <p><b>Pressedo®</b> Broad spectrum novel insecticide</p>	 <p><b>OsheenUltra®</b> For sucking pest control</p>	 <p><b>Solju™ Gr &amp; Solju™ SP</b> Unique microbial biofertiliser</p>	 <p><b>Dorito®</b> Broad spectrum insecticide</p>	 <p><b>BYROCK®</b> Fungicide</p>	 <p><b>Kapigin®</b> Organic Fertiliser</p>	 <p><b>Vachan™</b> Insecticide for Leps management</p>	
 <p><b>Claret®</b> Unique combination of systemic and contact insecticide</p>	 <p><b>Eketsu™</b> 1<sup>st</sup> 3-way Rice Herbicide</p>	 <p><b>Kadett®</b> Combination Fungicide</p>	 <p><b>Pilin®</b> Bio-fungicide with Novel Mode Of Action</p>	 <p><b>AminogrowActiv™</b> Amino acid &amp; Peptides product</p>	 <p><b>Campana™</b> New systematic insecticide</p>		

Source: Company, MOFSL



## Highlights from the management commentary

### Operating performance

- Agchem exports declined 15% amid continued contraction in the global agrochemical industry.
- Domestic revenue softened ~9% YoY despite ~3% volume growth, which was impacted by: elevated channel inventory levels resulting in pricing pressure; reduction in acreage of key crops; and regulatory transitions in the Biologicals segment moving toward normalization, with flat growth in 4QFY26.
- For FY26, Agchem exports declined 79% YoY (volumes down ~14%), primarily due to a high base effect, with YoY growth of +26% in FY23, +79% in FY24, and +5% in FY25. The company commercialized five molecules in FY26, while new products contributed 78% of Agchem export revenue.
- For FY26, domestic revenue declined ~7% YoY (volumes down ~1%), impacted by adverse weather conditions, lower crop prices, regulatory disruptions in the Biologicals segment, and elevated channel inventories. The company launched four products in FY26.
- Pharma revenue grew 23% YoY, while the Pharma segment contributed ~8% to export revenue.
- Gross margins expanded, supported by a favorable product mix and continued cost discipline.
- Overheads increased due to strategic investments in newer businesses and new product promotions (~4%).
- Effective tax rate (ETR) increased on account of a higher share of business from non-SEZ operations in 4QFY26; FY26 ETR stood at ~22%.
- Surplus cash net of debt is INR 34,265m, enabling the company to pursue future strategic investments for long-term sustainable growth.
- Total capex for FY26 stood at INR11.5b (FY25: INR9.3b), reflecting continued investment in manufacturing capabilities to meet future consumer requirements and R&D spends for molecule innovation.
- NWC stood flat QoQ at 139 days.
- The company became the first Indian player to develop and innovate 'PIOXANILIPROLE', which has now been filed for registration.
- More than 20 molecules have been commercialized over the past few years. More than 90 molecules are currently in the active pipeline, with over 60% in advanced stages of development. Pipeline ramp-up across diversified segments, with the share of non-agchem in new enquiries increasing from ~15% in FY20 to over 40% in FY26.

### Outlook and guidance

- In the domestic market, climatic uncertainties ahead of the Kharif season are expected to be partly offset by higher reservoir levels. Rising input costs amid ongoing geopolitical tensions continue to exert pricing pressure.
- In export, more than five new molecules are planned for launch in FY27, which is expected to accelerate growth. Management remains cautiously optimistic on 2HFY27, supported by committed customer offtake plans. A strong order book continues to underpin the FY27 growth outlook. Strategic investments in differentiated technologies remain ongoing.

- The Pharma segment is witnessing positive momentum, driven by new strategic partnerships established over the last 12 months. Visibility on business development opportunities and the R&D pipeline has improved over the next 1-2 years. Capacity expansion and enhancement initiatives are underway at the GMP facility in Lodi, Italy, along with non-GMP sites in India.
- Commercialization of the PI-owned NCE is targeted in FY27, while additional leads are progressing well under the partnership model.
- The company maintains a robust global pipeline of biological products across multiple stages of development.
- Inorganic growth opportunities are being evaluated to complement long-term growth plans.

### Capex

- The new product capacity is being developed as a multi-product facility.
- Across the Agrichemicals, Pharma, and R&D segments, the company has continued to invest significantly. A substantial portion of the spending was directed toward commercializing the Lodi facility, along with one of the NPP flows commissioned during the year on the agrichemicals side. Additionally, the company has been making ongoing investments in R&D capabilities.
- The company has guided for a capex of INR7-8b in FY27.

### Industry Environment

- The global crop protection market continues to witness a prolonged downcycle, with the recovery remaining uneven and further complicated by global events during the quarter. This has resulted in a clear shift towards just-in-time purchasing behavior among customers.
- The Middle East conflict towards the end of February introduced an additional layer of disruption that the industry had not anticipated. While these developments have created fresh challenges, they have also reinforced the strategic importance of geographical diversification. On the domestic front, the overall fundamentals remain encouraging, although near-term industry demand has been subdued due to elevated channel inventories, lower crop prices, and unseasonal rainfall. Despite this, the rabi season was favourable, supported by increased acreage, and the long-term structural drivers for the industry remain firmly intact.
- Agrochemicals are increasingly becoming a necessity for farmers, particularly at a time when commodity prices remain weak, fertilizer prices are elevated, and overall input costs are rising. As a result, farmers are currently seeking cost-effective solutions. However, opportunities continue to exist in segments where differentiated and innovative solutions add value. While the pace of adoption may have moderated temporarily, innovation and new molecules continue to gain acceptance. The current slowdown appears cyclical in nature, and adoption is expected to accelerate as the commodity cycle and broader agricultural sector recover.

### Pharma business

- Revenue growth was primarily driven by onboarding of new customers over the past 12 months, including several strategic accounts and large pharma clients, which are expected to support mid- to long-term growth.

- Margins were impacted by one-off processing-related costs and an unfavorable product mix.
- Overheads increased due to continued investments in capability building, talent addition, and process enhancement initiatives.
- Capex spending stood at ~INR91m versus ~INR1.3b in FY25.
- Enquiries in CDMO/CRO business increased from 54/15 in FY25 to 210/85 in FY26.
- Active customers in services increased from 16 in FY25 to 38 in FY26, while active customers in products reduced from 61 in FY25 to 48 in FY26.
- Capability building initiatives include filing for regulatory approval of the GMP Kilo facility in Lodi, establishing a Center of Excellence (CoE) for drug discovery at the Hyderabad CRO facility, and setting up a state-of-the-art QC laboratory in Lodi. The company has also strengthened its capabilities with advanced CADD and ML toolkits for large-scale library screening and Discovery Biology.
- The business may take a couple of years to achieve positive EBITDA.
- In the CDMO segment, the company is targeting revenues of INR5–6b over the next 2–3 years.

#### **Biological business**

- Harpin  $\alpha\beta$  was launched in India.
- The US EPA granted registration approval for the bionematocide product.
- The company is preparing to launch proprietary bionematocide and biostimulant brands in the eastern Rockies region.
- Distribution presence in Mexico was strengthened through onboarding of the country's second-largest national crop protection distributor.
- Global Biologicals (excluding India) has achieved an annualised revenue run-rate of ~USD12m, with healthy margins exceeding 60%, and is expected to deliver double-digit growth going forward.

#### **Biological Nematocide**

- Most biological nematode products are typically soil-applied; however, the company has introduced, for the first time, a foliar application-based product.
- The company expects significant growth from this product, with the US emerging as the third key market, alongside launches in Brazil and Mexico.
- The product is still in the early stages of development, but the company expects sales to more than triple this year. It competes effectively with synthetic chemistry-based alternatives and has received highly positive feedback from farmers in terms of performance.
- While farmer acceptance of biological products is still evolving, the initial response has been encouraging. Management believes it may take a couple of years to fully establish the product in the market, but the strong early results reinforce confidence in scaling investments and adopting an aggressive market-building strategy for this product category.

#### **Electronic chemicals**

- The business is currently in the ramp-up phase, with strong efforts underway in this segment. The products cater to niche and differentiated applications.
- The company aims to scale this segment to around INR10b over the next 4–5 years. Investments exceeding INR1b are planned in this area.

- Over time, the company expects this segment to generate revenues of INR5–6 b. Several products are still in the development stage, and the company expects to gain better visibility on the revenue potential over the next 2–3 years.

**Others**

- The company is witnessing pricing corrections and currency-related fluctuations under its pass-through model. Raw material price volatility has also had some impact. However, the company is balancing market dynamics while supporting customers amid end-market challenges, with a focus on maintaining sustainable growth, ensuring high utilization of its delivery plants, and managing margins effectively.
- The key focus remains on gaining market share through volume growth.
- Plant Healthcare contributes revenues of approximately USD 12–13m.
- Contract assets witnessed a significant reduction of nearly 30–35% during the last quarter of the year, primarily driven by asset utilization dynamics, product valuation adjustments, and long-chain products in the pipeline. Management expects contract assets to remain broadly at similar levels going forward, given the current business model and operating structure.

**Valuation and view**

- The company’s CSM business witnessed a sharp slowdown in FY26 due to weak industry demand, elevated channel inventories globally, and customers adopting a cautious just-in-time procurement strategy, resulting in volume decline.
- Going forward, we believe growth recovery will be led by: 1) improving growth prospects in the CSM business due to faster growth in new molecules (commercialization of 20+ molecules in the last few years ), ramp up of new molecules (18-20% share), strong pipeline of 90+ molecules ( >60% in advanced stages of development); 2) Commercialization of PI’s proprietary New Chemical Entity (NCE), which is targeted for FY27; 3) robust pipeline of biological products across various development stages; and 4) the ramp-up of its pharma business with profitable growth.
- We expect a CAGR of 13%/16%/14% in revenue/EBITDA/adj. PAT over FY26-28. **We reiterate our BUY rating with a TP of INR3,500 (based on 33x FY28E EPS, i.e. a discount of ~10% to the company’s six-year historical P/E at 37x).**

**Exhibit 9: Changes to our estimates**

Earnings Change (INR m)	Old		New		Change	
	FY27E	FY27E	FY27E	FY27E	FY27E	FY28E
Revenue	75,872	86,441	74,767	85,945	-1%	-1%
EBITDA	19,819	22,902	19,140	22,776	-3%	-1%
Adj. PAT	14,087	16,383	13,660	16,284	-3%	-1%

Source: MOFSL

## Financials and valuations

Income Statement (Consolidated)								(INRm)
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Gross Revenue	45,770	52,995	64,920	76,658	79,778	67,137	74,767	85,945
Excise Duty	0	0	0	0	0	0	0	0
<b>Net Revenue</b>	<b>45,770</b>	<b>52,995</b>	<b>64,920</b>	<b>76,658</b>	<b>79,778</b>	<b>67,137</b>	<b>74,767</b>	<b>85,945</b>
Change (%)	36.0	15.8	22.5	18.1	4.1	-15.8	11.4	15.0
Cost of Materials Consumed	25,712	29,228	35,527	38,376	37,711	28,333	31,776	36,527
% of Sales	56.2	55.2	54.7	50.1	47.3	42.2	42.5	42.5
Personnel Expenses	4,169	4,804	5,266	7,013	7,837	9,077	10,019	11,173
% of Sales	9.1	9.1	8.1	9.1	9.8	13.5	13.4	13.0
Other Expenses	5,767	7,539	8,706	11,123	12,440	12,731	13,832	15,470
% of Sales	12.6	14.2	13.4	14.5	15.6	19.0	18.5	18.0
<b>Total Expenditure</b>	<b>35,648</b>	<b>41,571</b>	<b>49,499</b>	<b>56,512</b>	<b>57,988</b>	<b>50,141</b>	<b>55,626</b>	<b>63,170</b>
% of Sales	77.9	78.4	76.2	73.7	72.7	74.7	74.4	73.5
<b>EBITDA</b>	<b>10,122</b>	<b>11,424</b>	<b>15,421</b>	<b>20,146</b>	<b>21,790</b>	<b>16,996</b>	<b>19,140</b>	<b>22,776</b>
Margin (%)	22.1	21.6	23.8	26.3	27.3	25.3	25.6	26.5
Depreciation	1,748	2,018	2,265	3,082	3,525	4,066	4,454	4,982
<b>EBIT</b>	<b>8,374</b>	<b>9,406</b>	<b>13,156</b>	<b>17,064</b>	<b>18,265</b>	<b>12,930</b>	<b>14,686</b>	<b>17,793</b>
Int. and Finance Charges	282	128	371	300	330	164	164	164
Other Income	1,249	1,014	1,590	2,078	3,442	3,107	3,140	3,438
<b>PBT bef. EO Exp.</b>	<b>9,341</b>	<b>10,292</b>	<b>14,375</b>	<b>18,842</b>	<b>21,377</b>	<b>15,873</b>	<b>17,662</b>	<b>21,067</b>
EO Items	0	0	0	0	0	-1,031	0	0
<b>PBT after EO Exp.</b>	<b>9,341</b>	<b>10,292</b>	<b>14,375</b>	<b>18,842</b>	<b>21,377</b>	<b>16,904</b>	<b>17,662</b>	<b>21,067</b>
Current Tax	1,753	1,950	2,592	2,132	4,818	3,753	4,062	4,845
Deferred Tax	249	-60	-444	0	0	0	0	0
Tax Rate (%)	21.4	18.4	14.9	11.3	22.5	22.2	23.0	23.0
Less: MI/Profit & Loss of associates	-44	-36	-68	-105	-43	-57	-60	-63
<b>Reported PAT</b>	<b>7,383</b>	<b>8,438</b>	<b>12,295</b>	<b>16,815</b>	<b>16,602</b>	<b>13,208</b>	<b>13,660</b>	<b>16,284</b>
<b>Adjusted PAT</b>	<b>7,383</b>	<b>8,438</b>	<b>12,295</b>	<b>16,815</b>	<b>16,602</b>	<b>12,435</b>	<b>13,660</b>	<b>16,284</b>
Change (%)	61.7	14.3	45.7	36.8	-1.3	-25.1	9.9	19.2
Margin (%)	16.1	15.9	18.9	21.9	20.8	18.5	18.3	18.9

Balance Sheet (Consolidated)								(INRm)
Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	152.0	152.0	152.0	152.0	152.0	152.0	152.0	152.0
Total Reserves	53,272	61,052	71,833	87,158	1,01,418	1,12,153	1,23,381	1,37,233
<b>Net Worth</b>	<b>53,424</b>	<b>61,204</b>	<b>71,985</b>	<b>87,310</b>	<b>1,01,570</b>	<b>1,12,305</b>	<b>1,23,533</b>	<b>1,37,385</b>
Deferred Liabilities	796	875	213	202	551	384	384	384
Total Loans	3,279	2,678	0	1,279	1,117	2,383	2,383	2,383
<b>Capital Employed</b>	<b>57,499</b>	<b>64,757</b>	<b>72,198</b>	<b>88,791</b>	<b>1,03,238</b>	<b>1,15,072</b>	<b>1,26,300</b>	<b>1,40,152</b>
Gross Block	28,921	34,082	37,877	47,404	55,805	63,492	71,492	79,492
Less: Accum. Deprn.	8,367	10,385	12,650	15,732	19,257	23,323	27,777	32,759
<b>Net Fixed Assets</b>	<b>20,554</b>	<b>23,697</b>	<b>25,227</b>	<b>31,672</b>	<b>36,548</b>	<b>40,169</b>	<b>43,715</b>	<b>46,732</b>
Goodwill on Consolidation	0	0	0	0	0	0	342	683
Capital WIP	2,875	1,145	1,324	2,781	5,502	7,550	6,550	5,550
Current Investments	8,517	8,547	9,843	13,028	12,598	13,271	14,271	15,271
<b>Total Investments</b>	<b>8,724</b>	<b>8,995</b>	<b>10,156</b>	<b>13,341</b>	<b>15,314</b>	<b>13,603</b>	<b>14,603</b>	<b>15,603</b>
<b>Curr. Assets, Loans&amp;Adv.</b>	<b>37,866</b>	<b>44,074</b>	<b>48,090</b>	<b>59,846</b>	<b>65,403</b>	<b>73,115</b>	<b>79,809</b>	<b>92,992</b>
Inventory	10,528	14,234	13,976	13,012	9,839	12,167	13,315	15,305
Account Receivables	7,035	8,687	7,720	9,299	14,058	16,108	11,266	12,951
Cash and Bank Balance	14,757	14,102	22,429	27,039	24,996	21,823	29,808	38,093
Loans and Advances	5,546	7,051	3,965	10,496	16,510	23,017	25,421	26,643
<b>Curr. Liability &amp; Prov.</b>	<b>12,520</b>	<b>13,154</b>	<b>12,599</b>	<b>18,849</b>	<b>19,529</b>	<b>19,365</b>	<b>18,719</b>	<b>21,409</b>
Account Payables	7,960	9,242	8,380	11,484	12,102	9,738	8,270	9,507
Other Current Liabilities	4,008	3,555	3,838	6,635	6,875	8,898	9,720	11,173
Provisions	552	357	381	730	552	729	729	729
<b>Net Current Assets</b>	<b>25,346</b>	<b>30,920</b>	<b>35,491</b>	<b>40,997</b>	<b>45,874</b>	<b>53,750</b>	<b>61,090</b>	<b>71,583</b>
<b>Appl. of Funds</b>	<b>57,499</b>	<b>64,757</b>	<b>72,198</b>	<b>88,791</b>	<b>1,03,238</b>	<b>1,15,072</b>	<b>1,26,300</b>	<b>1,40,152</b>

## Financials and valuations

### Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
<b>Basic (INR)</b>								
<b>EPS</b>	<b>48.6</b>	<b>55.5</b>	<b>80.9</b>	<b>110.6</b>	<b>109.2</b>	<b>81.8</b>	<b>89.9</b>	<b>107.1</b>
Cash EPS	60.1	68.8	95.8	130.9	132.4	108.6	119.2	139.9
BV/Share	351.5	402.7	473.6	574.4	668.2	738.8	812.7	903.8
DPS	5.0	5.0	10.0	10.0	16.0	16.0	16.0	16.0
Payout (%)	10.3	9.0	12.4	9.0	14.6	18.4	17.8	14.9
<b>Valuation (x)</b>								
P/E	59.8	52.3	35.9	26.2	26.6	35.5	32.3	27.1
Cash P/E	48.3	42.2	30.3	22.2	21.9	26.7	24.4	20.8
P/BV	8.3	7.2	6.1	5.1	4.3	3.9	3.6	3.2
EV/Sales	9.4	8.1	6.5	5.4	5.2	6.3	5.5	4.7
EV/EBITDA	42.5	37.6	27.2	20.6	19.2	24.8	21.6	17.8
Dividend Yield (%)	0.2	0.2	0.3	0.3	0.6	0.6	0.6	0.6
FCF per share	18.9	12.7	77.3	61.7	19.8	-32.9	78.4	80.4
<b>Return Ratios (%)</b>								
EBITDA Margins (%)	22.1	21.6	23.8	26.3	27.3	25.3	25.6	26.5
Net Profit Margins (%)	16.1	15.9	18.9	21.9	20.8	18.5	18.3	18.9
RoE	18.5	14.7	18.5	21.1	17.6	11.6	11.6	12.5
RoCE	17.2	14.1	18.5	21.1	17.6	11.5	11.4	12.3
RoIC	22.8	21.4	28.4	36.1	27.5	15.5	15.3	17.5
<b>Working Capital Ratios</b>								
Accum. Dep/Gross Block (x)	0	0	0	0	0	0	0	0
Fixed Asset Turnover (x)	1.6	1.6	1.7	1.6	1.4	1.1	1	1
Asset Turnover (x)	0.8	0.8	0.9	0.9	0.8	0.6	0.6	0.6
Inventory (Days)	84	98	79	62	45	66	65	65
Debtor (Days)	56	60	43	44	64	88	55	55
Creditor (Days)	113	115	86	109	117	125	95	95
Working Cap. Turnover (Days)	84	116	73	66	96	174	153	142
<b>Leverage Ratio (x)</b>								
Current Ratio	3.0	3.4	3.8	3.2	3.3	3.8	4.3	4.3
Interest Cover Ratio	30	73	35	57	55	79	90	108
Debt/Equity	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0

### Cash Flow Statement (Consolidated)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
<b>(INRm)</b>								
OP/(Loss) before Tax	9,385	10,328	14,443	18,842	21,377	15,873	17,662	21,067
Depreciation	1,748	2,018	2,265	3,082	3,525	4,066	4,454	4,982
Interest & Finance Charges	282	128	371	300	330	164	164	164
Direct Taxes Paid	-1,647	-1,751	-2,558	-2,132	-4,818	-3,753	-4,062	-4,845
(Inc)/Dec in WC	-1,303	-5,276	2,050	162	-6,327	-12,698	645	-2,208
<b>CF from Operations</b>	<b>8,465</b>	<b>5,447</b>	<b>16,571</b>	<b>20,254</b>	<b>14,087</b>	<b>3,652</b>	<b>18,863</b>	<b>19,160</b>
Others	-1,216	-160	-1,557	105	43	1,088	60	63
<b>CF from Operating incl EO</b>	<b>7,249</b>	<b>5,287</b>	<b>15,014</b>	<b>20,359</b>	<b>14,130</b>	<b>4,740</b>	<b>18,923</b>	<b>19,223</b>
(inc)/dec in FA	-4,375	-3,362	-3,263	-10,984	-11,122	-9,735	-7,000	-7,000
<b>Free Cash Flow</b>	<b>2,874</b>	<b>1,925</b>	<b>11,751</b>	<b>9,375</b>	<b>3,008</b>	<b>-4,995</b>	<b>11,923</b>	<b>12,223</b>
(Pur)/Sale of Investments	-5,516	39	-941	-7,076	-2,315	1,369	-1,342	-1,342
Others	-14,413	2,219	-758	55	-805	2,231	0	0
<b>CF from Investments</b>	<b>-24,304</b>	<b>-1,104</b>	<b>-4,962</b>	<b>-18,005</b>	<b>-14,242</b>	<b>-6,135</b>	<b>-8,342</b>	<b>-8,342</b>
Issue of Shares	19,736	0	0	0	0	0	0	0
Inc/(Dec) in Debt	-1,786	-720	-2,669	1,279	-162	1,266	0	0
Interest Paid	-244	-85	-342	-300	-330	-164	-164	-164
Dividend Paid	-607	-758	-1,137	-1,520	-2,432	-2,432	-2,432	-2,432
Others	13,371	-3,275	2,423	2,797	993	-448	0	0
<b>CF from Fin. Activity</b>	<b>30,470</b>	<b>-4,838</b>	<b>-1,725</b>	<b>2,256</b>	<b>-1,931</b>	<b>-1,778</b>	<b>-2,596</b>	<b>-2,596</b>
<b>Inc/Dec of Cash</b>	<b>13,415</b>	<b>-655</b>	<b>8,327</b>	<b>4,610</b>	<b>-2,043</b>	<b>-3,173</b>	<b>7,985</b>	<b>8,285</b>
Opening Balance	1,342	14,757	14,102	22,429	27,039	24,996	21,823	29,808
<b>Closing Balance</b>	<b>14,757</b>	<b>14,102</b>	<b>22,429</b>	<b>27,039</b>	<b>24,996</b>	<b>21,823</b>	<b>29,808</b>	<b>38,093</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

## NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

**Disclosures**

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH00000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://qalaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on [www.motilaloswal.com](http://www.motilaloswal.com) > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

**Regional Disclosures (outside India)**

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

**For Hong Kong:**

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH00000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

**For U.S.**

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

**For Singapore**

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

**Specific Disclosures**

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

**Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

**Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

**Disclaimer:**

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email

Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX), CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.